Filgotinib for moderately to severely active ulcerative colitis.

Alessandro MannucciFerdinando D'AmicoAhmad El SaadiLaurent Peyrin-BirouletSilvio Danese

Published in: Expert review of gastroenterology & hepatology (2022)

Filgotinib has remarkable efficacy, safety, and tolerability profiles in the treatment of moderate-to-severe active UC. It can be used in both biologic-naïve and biologic-experienced patients. The rapid mechanism of action and its oral administration route make it a reliable therapeutic option.

Keyphrases

rheumatoid arthritis
end stage renal disease
ulcerative colitis
ejection fraction
chronic kidney disease
randomized controlled trial
open label
study protocol
sensitive detection
loop mediated isothermal amplification